Marc S. Ernstoff

Research interests

Publications

• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

  Journal for ImmunoTherapy of Cancer · 2021 · https://doi.org/10.1136/jitc-2021-002435

• NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

  Journal of the National Comprehensive Cancer Network · 2020 · https://doi.org/10.6004/jnccn.2020.0012

• Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2019 · https://doi.org/10.6004/jnccn.2019.0013

• Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.2244

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1805453

• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.77.6385

• Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

  Journal for ImmunoTherapy of Cancer · 2017 · https://doi.org/10.1186/s40425-017-0300-z

• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1414428

• Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls

  International Journal of Epidemiology · 2009 · https://doi.org/10.1093/ije/dyp166

Current projects

No projects listed.